glp-1 ckd FLOWing with the SemagluTIDE — NephJC The privileged position of glp-1

Clinical trials have shown that weight loss with these medications typically ranges from 10-20% of body weight, depending on the specific agent and dosage, with tirzepatide showing the highest average weight reduction

Beginning July 1, 2026, the Medicare GLP-1 Bridge will cover select medications including Foundayo, Wegovy and Zepbound KwikPen for eligible Part D participants

Supplied as a 20 mg lyophilized peptide with full COA traceability

Someone with diabetes, thyroid disease, or a history of pancreatitis could experience harmful effects from unvetted herbal formulations that lack safety data in clinical populations

Nutritional support during GLP-1 treatment cannot be overstated

Food and Drug Administration doesnt monitor the manufacture or sale of supplements or herbs